Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 382 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NSCLC, Stage IIIA Clear all
Completed Phase 2Phase 3 Interventional

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

NCT00002930
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer
Interventions
positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jun 10, 2026, 8:49 AM EDT
Active, not recruiting Phase 1 Interventional

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

NCT05166616
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Biopsy, Osimertinib, Triptolide Analog
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 2 Interventional

EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00041028
View directory record Official record
Conditions
Lung Cancer
Interventions
EF5, flow cytometry, immunohistochemistry staining method
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jun 10, 2026, 8:49 AM EDT
Withdrawn Phase 2 Interventional

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

NCT03628144
View directory record Official record
Conditions
Non Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage ⅢA, NSCLC Stage IIIB, NSCLC, Stage IIIA
Interventions
Impact® Advanced Recovery, Boost® High Protein, Radiation Therapy, Chemotherapy, Quality of life (EORTC-QLQ-30), Evaluation of Cognitive Function (FACT-Cog, v. 3.0), Mindfulness Questionnaire (FFMQ)
Dietary Supplement · Radiation · Drug + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Not applicable Interventional

Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer

NCT00310219
View directory record Official record
Conditions
Lung Cancer
Interventions
computed tomography, positron emission tomography
Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
St Louis, Missouri • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 2 Interventional

Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

NCT00081302
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jun 10, 2026, 8:49 AM EDT
Terminated Phase 3 Interventional Results available

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

NCT03447769
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
21
States / cities
Fayetteville, Arkansas • Los Alamitos, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Not applicable Interventional

Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer

NCT01741636
View directory record Official record
Conditions
Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions
educational intervention, questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 2 Interventional

EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer

NCT02154399
View directory record Official record
Conditions
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions
EF5, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Tissue Oxygen Measurement
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Jun 10, 2026, 8:49 AM EDT
Active, not recruiting Phase 3 Interventional

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

NCT01993810
View directory record Official record
Conditions
Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Radiation + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
30
States / cities
Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

NCT00193427
View directory record Official record
Conditions
Lung Cancer
Interventions
Docetaxel, Gemcitabine, Carboplatin, Radiation
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery

NCT00006470
View directory record Official record
Conditions
Lung Cancer
Interventions
monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, radiation therapy
Biological · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
218
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

NCT00577707
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer
Interventions
erlotinib, Pemetrexed, Cisplatin, Resection
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Jun 10, 2026, 8:49 AM EDT
Recruiting Phase 3 Interventional

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
243
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Loma Linda, California + 193 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 8:49 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer

NCT01629498
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Questionnaire Administration
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 10, 2026, 8:49 AM EDT
Completed No phase listed Observational

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

NCT00450567
View directory record Official record
Conditions
Lung Cancer
Interventions
computed tomography, positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 2 Interventional

Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

NCT00062179
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, celecoxib, paclitaxel, Placebo
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jun 10, 2026, 8:49 AM EDT
Terminated Phase 1 Interventional

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

NCT02134886
View directory record Official record
Conditions
HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Not applicable Interventional

Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer

NCT00900835
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Fatigue, Lung Cancer, Pain, Prostate Cancer
Interventions
educational intervention, questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, fatigue assessment and management, quality-of-life assessment, standard follow-up care
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Early Phase 1 Interventional Results available

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

NCT01434342
View directory record Official record
Conditions
Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Nicotine Replacement Patch
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00547105
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, SBRT
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 1 Interventional

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00734890
View directory record Official record
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Jun 10, 2026, 8:49 AM EDT
Completed Phase 1 Interventional

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00310154
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy
Drug · Other · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jun 10, 2026, 8:49 AM EDT